Aug 1 |
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
|
Jul 31 |
Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings
|
Jul 26 |
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
|
Jul 25 |
FDA agrees wider use of BioMarin’s BRINEURA for CLN2
|
Jul 24 |
BioMarin gets expanded FDA approval for CLN2 therapy Brineura
|
Jul 24 |
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease
|
Jul 24 |
Why BioMarin (BMRN) is Poised to Beat Earnings Estimates Again
|
Jul 24 |
BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
|
Jul 23 |
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
|
Jul 23 |
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET
|